At the University of Maryland Medical Center (UMMC), interventional radiology and interventional oncology are precision-targeted treatments for cancers and vascular conditions, relying on the latest technology and expert care to enhance patient outcomes and quality of life. We take an innovative approach to treatment that uses minimally invasive techniques. This allows for faster recovery, fewer side effects and less pain than other treatment options.
UMMC also offers clinical trials that present further treatment options for patients with cancer or vascular conditions. Additionally, we have one of the region's most comprehensive and innovative liver cancer clinical trials.
We give patients comprehensive consults with the latest treatment and clinical trial options.
Please consider reaching out if you or your loved ones want to learn more. You can contact Aerial Kendrick at 410-328-3631 to learn about the innovative and novel clinical trials we have open.
View interventional radiology (IR) clinical trials for the following:
2298GCCC | A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3)
Principal Investigator: Kevin Kim, MD
Sites:
Learn More: Find contact and eligibility information for this clinical trial.
2296GCCC | A Phase 1b/2 Pressure Enabled Regional Immuno-Oncology Study of Hepatic Arterial Infusion of SD-101 with Systemic Checkpoint Blockade for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Principal Investigator: Kevin Kim, MD
Sites:
Learn More: Find contact and eligibility information for this clinical trial.
21132GCCC | CSR02-TF as Hepatic Intra-arterial Therapy in Intermediate Stage B or Limited Advanced Stage C Hepatocellular Carcinoma (HCC): Dose-Escalation Study to Assess Safety and Tolerability
Principal Investigator: Kevin Kim, MD
Sites:
Learn More: Find contact and eligibility information for this clinical trial.
2297GCCC | An Open-Label, Multicenter, Phase 1 Study of RP3 as a Single Agent and in Combination with PD-1 Blockade in Patients with Solid Tumors
Principal Investigator: Kevin Kim, MD
Sites:
Learn More: Find contact and eligibility information for this clinical trial.
NCT05364502 | Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial Bleeds (HALT)
Principal Investigator: Adam Fang, MD
Sites:
Learn More: Find contact and eligibility information for this clinical trial.
